WATERTOWN, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Tec…
Category: Business
Aerpio Pharmaceuticals Presents Data Showing Potential of AKB-9778, a VE-PTP Inhibitor/Tie2 Activator, to Lower Intra-ocular Pressure in Human Subjects
CINCINNATI–(BUSINESS WIRE)–Aerpio Pharmaceuticals, Inc. (NASDAQ: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, presented data showing the potential of AKB-97…
Multiple Surgeons to Present Data on Glaukos Technologies at 2019 American Society of Cataract and Refractive Surgery
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies desig…
STAAR Surgical Announces Expanded Recommended Diopter Range for EVO Visian ICL by Refractive Societies in Germany and Japan
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced the leading refractive ophthalmic societies in…
STAAR Surgical Reports First Quarter Results
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the first quarter ended M…
Ocular Therapeutix Announces DEXTENZA® (dexamethasone ophthalmic insert) Recommended for Unique J-Code by CMS
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix Announces DEXTENZA® (dexamethasone ophthalmic insert) Recommended for Unique J-Code by CMS
Omeros Corporation Announces Presentation of OMIDRIA® Real-World Data at Upcoming American Society of Cataract and Refractive Surgery Annual Meeting
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER) today announced that the results of an investigator-sponsored real-world study of its FDA-approved ophthalmic drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% will be…
IVERIC bio to Report First Quarter 2019 Financial Results and Host Conference Call on Wednesday, May 8, 2019
NEW YORK–(BUSINESS WIRE)–IVERIC bio announced that it will report its first quarter 2019 financial and operating results on Wednesday, May 8, 2019 at 8:00am ET.
Eyenuks AI Eye Screening-System für diabetische Retinopathie zeigt außergewöhnliche Leistung in einer prospektiven, multizentrischen, klinischen Schlüsselstudie.
LOS ANGELES–(BUSINESS WIRE)–Eyenuk, Inc., ein weltweit tätiges Unternehmen für Medizintechnik und medizinische Dienstleistungen im Bereich der künstlichen Intelligenz (KI, engl. Artificial Intelligence (AI)) und Marktführer bei Anwendungen für AI Eye…
Le système de dépistage oculaire basé sur l’IA d’Eyenuk pour la rétinopathie diabétique démontre des performances exceptionnelles dans un essai clinique pivot, multicentrique et prospectif
LOS ANGELES–(BUSINESS WIRE)–Eyenuk, Inc., société mondiale de technologies et services médicaux basés sur l’intelligence artificielle (IA), qui se démarque en tant que leader dans le domaine des applications en situation réelle pour le dépistage ocul…
El AI Eye Screening System (sistema de exploración ocular vía IA), de Eyenuk, para retinopatía diabética demuestra un rendimiento excepcional en un ensayo clínico prospectivo, fundamental realizado en múltiples centros
LOS ÁNGELES–(BUSINESS WIRE)–Eyenuk, Inc., una compañía global de tecnología y servicios médicos vía inteligencia artificial (IA) y líder en aplicaciones en el mundo real para IA Eye Screening™, hoy anunció los resultados de su ensayo clínico prospect…
Allegro Ophthalmics to Present the Results of Its ALG-1007 Ex-U.S. Trial for Dry Eye Disease at the 2019 ASCRS•ASOA Annual Meeting
SAN JUAN CAPISTRANO, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/ASCRS?src=hash" target="_blank"gt;#ASCRSlt;/agt;–Allegro Ophthalmics announced that the results of its ALG-1007 ex-U.S. clinical t…
Sistema de avaliação ocular que faz uso de inteligência artificial da Eyenuk para retinopatia diabética demonstra excelente desempenho em um estudo clínico fundamental, prospectivo e multicêntrico
LOS ANGELES–(BUSINESS WIRE)–A Eyenuk, Inc., empresa de serviços e tecnologia médica que faz uso de inteligência artificial (artificial intelligence, AI) e líder em aplicações do mundo real para avaliação ocular usando AI Eye Screening™, anunciou hoje…
Samenvatting: Eyenuk’s AI-oogcontrolesysteem voor diabetische retinopathie toont uitzonderlijke prestaties in een prospectieve cruciale klinische studie
LOS ANGELES–(BUSINESS WIRE)–Eyenuk, Inc., een internationaal bedrijf op het gebied van kunstmatige intelligentie (AI) en medische technologie en services en de leider in real-world toepassingen voor AI Eye Screening™, heeft vandaag de resultaten beke…
Riassunto: Allotex annuncia l'inizio della fase finale dei suoi studi clinici sulla presbiopia
BOSTON–(BUSINESS WIRE)–Allotex, società privata con sede a Boston impegnata nello sviluppo di lenticoli TransForm Corneal Allograft (TCA) per il trattamento della presbiopia (necessità di occhiali da lettura) e dell’ipermetropia (ipometropia), è lieta di annunciare il trattamento di oltre 50 occhi nella prima fase dei suoi studi clinici. I lenticoli TCA vengono creati a partire da tessuto corneale umano naturale modellato grazie a una tecnologia brevettata e proprietaria ad alta precisione; i
Allotex meldet Beginn der letzten klinischen Studienphase zu Presbyopie
BOSTON–(BUSINESS WIRE)–Allotex, ein in Boston ansässiges Privatunternehmen, das das TransForm Corneal Allograft (TCA) zur Behandlung von Presbyopie (Lesebrille) und Hyperopie (Weitsichtigkeit) entwickelt, meldet die Durchführung von mehr als 50 Augen…
Allotex annonce le début de la phase finale des essais cliniques sur la presbytie
BOSTON–(BUSINESS WIRE)–Allotex, une société privée basée à Boston qui développe l’allogreffe cornéenne TransForm (TCA) pour le traitement de la presbytie (lunettes de lecture) et de l’hypermétropie (vision de loin), est ravie de pouvoir annoncer qu’une première phase des études cliniques a été consacrée à plus de 50 yeux. La TCA est créée à partir de tissu cornéen humain naturel qui a été façonné à l’aide d’une technologie brevetée et exclusive de haute précision. Ces lenticules façonnées son
Verseon Presents Oral Drug Candidate for Diabetic Eye Disease That Could Replace Eye Injections
FREMONT, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/biotech?src=hash" target="_blank"gt;#biotechlt;/agt;–Verseon presented their first DME development candidate at ARVO 2019. The candidate could…
Allotex Announces Commencement of Final Phase of Presbyopia Clinical Trials
BOSTON–(BUSINESS WIRE)–Allotex, a Boston based private company developing the TransForm Corneal Allograft (TCA) for the treatment of presbyopia (reading glasses) and hyperopia (far sightedness), is pleased to report that over 50 eyes have been treate…
Riassunto: Il sistema di esame del fondo oculare basato su intelligenza artificiale per la retinopatia diabetica di Eyenuk dimostra prestazioni eccezionali in uno studio clinico registrativo, prospettico e multicentro
LOS ANGELES–(BUSINESS WIRE)–Eyenuk Inc., fornitore globale di tecnologie e servizi medici basati su intelligenza artificiale (IA), nonché leader nelle applicazioni nel mondo reale della tecnologia IA Eye Screening™, ha annunciato oggi i risultati eme…